 Michael Wachs
Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 53 | 2022 | 911 | 3.240 |
Why?
| | Living Donors | 16 | 2022 | 311 | 0.950 |
Why?
| | Donor Selection | 3 | 2021 | 74 | 0.810 |
Why?
| | Tissue Donors | 4 | 2021 | 355 | 0.800 |
Why?
| | Airway Extubation | 2 | 2022 | 45 | 0.760 |
Why?
| | Carcinoma, Hepatocellular | 7 | 2010 | 187 | 0.630 |
Why?
| | Immunosuppressive Agents | 16 | 2013 | 681 | 0.610 |
Why?
| | Liver Neoplasms | 7 | 2010 | 466 | 0.540 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2016 | 145 | 0.510 |
Why?
| | Cholestasis | 1 | 2016 | 230 | 0.460 |
Why?
| | Sirolimus | 8 | 2013 | 200 | 0.440 |
Why?
| | Graft Survival | 13 | 2022 | 498 | 0.400 |
Why?
| | Hypoxia | 1 | 2016 | 981 | 0.360 |
Why?
| | Biliary Atresia | 2 | 2022 | 215 | 0.340 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2006 | 35 | 0.330 |
Why?
| | Liver Failure | 5 | 2008 | 95 | 0.300 |
Why?
| | Tissue and Organ Procurement | 6 | 2022 | 252 | 0.290 |
Why?
| | Graft Rejection | 10 | 2008 | 600 | 0.290 |
Why?
| | Portal Vein | 1 | 2006 | 90 | 0.280 |
Why?
| | Venous Thrombosis | 1 | 2006 | 143 | 0.260 |
Why?
| | Retrospective Studies | 21 | 2022 | 13053 | 0.250 |
Why?
| | Vena Cava, Inferior | 1 | 2004 | 52 | 0.240 |
Why?
| | Treatment Outcome | 18 | 2022 | 9648 | 0.230 |
Why?
| | Cholangitis, Sclerosing | 4 | 2008 | 75 | 0.220 |
Why?
| | Vascular Surgical Procedures | 1 | 2004 | 276 | 0.200 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2021 | 70 | 0.200 |
Why?
| | Middle Aged | 34 | 2021 | 28928 | 0.200 |
Why?
| | End Stage Liver Disease | 1 | 2021 | 80 | 0.190 |
Why?
| | Cause of Death | 3 | 2021 | 400 | 0.180 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 238 | 0.170 |
Why?
| | Kidney Transplantation | 4 | 2003 | 561 | 0.170 |
Why?
| | Cyclosporine | 8 | 2008 | 181 | 0.170 |
Why?
| | Tacrolimus | 8 | 2008 | 151 | 0.170 |
Why?
| | Humans | 60 | 2022 | 121723 | 0.160 |
Why?
| | Liver | 7 | 2022 | 1832 | 0.160 |
Why?
| | Hepatitis B | 2 | 1996 | 54 | 0.160 |
Why?
| | Reoperation | 4 | 2016 | 578 | 0.160 |
Why?
| | Waiting Lists | 3 | 2022 | 226 | 0.160 |
Why?
| | Drug Overdose | 1 | 2021 | 283 | 0.160 |
Why?
| | Liver Cirrhosis | 3 | 2013 | 241 | 0.150 |
Why?
| | Hepatitis C | 2 | 2013 | 230 | 0.150 |
Why?
| | Pancreas Transplantation | 3 | 2003 | 70 | 0.150 |
Why?
| | Male | 38 | 2021 | 60425 | 0.140 |
Why?
| | Hepatic Artery | 3 | 2004 | 51 | 0.140 |
Why?
| | Child | 10 | 2022 | 19271 | 0.140 |
Why?
| | Time Factors | 10 | 2021 | 6885 | 0.140 |
Why?
| | Acute Kidney Injury | 1 | 2022 | 651 | 0.140 |
Why?
| | Adult | 26 | 2021 | 32638 | 0.140 |
Why?
| | Hepatitis B Core Antigens | 1 | 1995 | 5 | 0.140 |
Why?
| | Hepatitis B Surface Antigens | 1 | 1995 | 19 | 0.130 |
Why?
| | Female | 37 | 2021 | 63833 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2010 | 883 | 0.130 |
Why?
| | Shock | 1 | 2016 | 95 | 0.130 |
Why?
| | Hepatitis, Autoimmune | 2 | 2008 | 34 | 0.130 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 405 | 0.130 |
Why?
| | Hemoglobins | 1 | 2016 | 294 | 0.120 |
Why?
| | Erythrocyte Transfusion | 1 | 2016 | 210 | 0.120 |
Why?
| | Muromonab-CD3 | 3 | 2010 | 23 | 0.120 |
Why?
| | Cadaver | 3 | 2004 | 321 | 0.120 |
Why?
| | Postoperative Complications | 5 | 2021 | 2321 | 0.120 |
Why?
| | Immunoglobulin M | 1 | 1995 | 249 | 0.120 |
Why?
| | Glucocorticoids | 4 | 2003 | 553 | 0.120 |
Why?
| | Methylene Blue | 1 | 2012 | 25 | 0.110 |
Why?
| | Hepatectomy | 2 | 2008 | 137 | 0.110 |
Why?
| | Risk Factors | 7 | 2021 | 9403 | 0.110 |
Why?
| | Vasoconstrictor Agents | 1 | 2012 | 128 | 0.100 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 14 | 0.100 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2013 | 200 | 0.100 |
Why?
| | Triiodothyronine | 1 | 2011 | 43 | 0.100 |
Why?
| | Thyroxine | 1 | 2011 | 64 | 0.100 |
Why?
| | Hypotension | 1 | 2012 | 134 | 0.100 |
Why?
| | Mycophenolic Acid | 3 | 2008 | 79 | 0.100 |
Why?
| | Hypothyroidism | 1 | 2011 | 69 | 0.100 |
Why?
| | Adolescent | 8 | 2022 | 19118 | 0.100 |
Why?
| | Portography | 2 | 2006 | 9 | 0.090 |
Why?
| | Heart Transplantation | 1 | 1995 | 759 | 0.090 |
Why?
| | Budd-Chiari Syndrome | 2 | 1999 | 9 | 0.090 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2013 | 329 | 0.080 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 842 | 0.080 |
Why?
| | Chemoembolization, Therapeutic | 2 | 2007 | 33 | 0.080 |
Why?
| | Hepatic Veins | 1 | 2008 | 35 | 0.080 |
Why?
| | Infant | 4 | 2022 | 8439 | 0.080 |
Why?
| | Adrenal Cortex Hormones | 2 | 2008 | 525 | 0.080 |
Why?
| | Liver Diseases | 4 | 2002 | 324 | 0.080 |
Why?
| | Calcineurin Inhibitors | 2 | 2008 | 64 | 0.080 |
Why?
| | Recurrence | 5 | 2013 | 1001 | 0.080 |
Why?
| | Biomarkers | 2 | 2016 | 3650 | 0.080 |
Why?
| | Risk Assessment | 4 | 2022 | 3245 | 0.080 |
Why?
| | Prednisone | 2 | 1997 | 239 | 0.070 |
Why?
| | Ultrasonics | 1 | 2006 | 54 | 0.070 |
Why?
| | Follow-Up Studies | 6 | 2008 | 4880 | 0.070 |
Why?
| | Disease Transmission, Infectious | 1 | 2006 | 59 | 0.070 |
Why?
| | Herpes Simplex | 1 | 2006 | 93 | 0.070 |
Why?
| | Patient Selection | 4 | 2004 | 716 | 0.070 |
Why?
| | Treatment Failure | 1 | 2006 | 343 | 0.070 |
Why?
| | Elective Surgical Procedures | 1 | 2006 | 169 | 0.070 |
Why?
| | Intestinal Fistula | 1 | 2004 | 11 | 0.070 |
Why?
| | Duodenal Diseases | 1 | 2004 | 11 | 0.070 |
Why?
| | Vascular Fistula | 1 | 2004 | 17 | 0.070 |
Why?
| | Young Adult | 2 | 2021 | 11215 | 0.060 |
Why?
| | Aneurysm, False | 1 | 2004 | 42 | 0.060 |
Why?
| | Transplants | 1 | 2004 | 38 | 0.060 |
Why?
| | Nephrotic Syndrome | 1 | 2003 | 29 | 0.060 |
Why?
| | Outpatients | 1 | 2006 | 333 | 0.060 |
Why?
| | Hepatocytes | 1 | 2003 | 199 | 0.060 |
Why?
| | Renal Replacement Therapy | 1 | 2022 | 64 | 0.050 |
Why?
| | Ultrasonography | 1 | 2006 | 736 | 0.050 |
Why?
| | Hospital Costs | 1 | 2003 | 117 | 0.050 |
Why?
| | Portoenterostomy, Hepatic | 1 | 2022 | 64 | 0.050 |
Why?
| | Hepatic Encephalopathy | 2 | 1999 | 20 | 0.050 |
Why?
| | Liver Failure, Acute | 2 | 1998 | 67 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 3 | 2006 | 2519 | 0.050 |
Why?
| | Survival Analysis | 4 | 2008 | 1356 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2001 | 136 | 0.050 |
Why?
| | Drug Therapy, Combination | 4 | 2008 | 1003 | 0.050 |
Why?
| | Aged | 10 | 2021 | 20688 | 0.050 |
Why?
| | Remission Induction | 1 | 2020 | 255 | 0.050 |
Why?
| | Child, Preschool | 3 | 2022 | 9771 | 0.050 |
Why?
| | Prednisolone | 1 | 1999 | 76 | 0.040 |
Why?
| | Biopsy | 4 | 2006 | 1089 | 0.040 |
Why?
| | Mesenteric Veins | 1 | 1998 | 11 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 1998 | 146 | 0.040 |
Why?
| | Ascites | 2 | 2013 | 38 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2022 | 568 | 0.040 |
Why?
| | Portasystemic Shunt, Surgical | 1 | 1997 | 9 | 0.040 |
Why?
| | Thrombectomy | 1 | 1998 | 59 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3172 | 0.040 |
Why?
| | Length of Stay | 1 | 2022 | 1056 | 0.040 |
Why?
| | Thrombolytic Therapy | 1 | 1998 | 120 | 0.040 |
Why?
| | Critical Illness | 1 | 2022 | 663 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1997 | 204 | 0.040 |
Why?
| | Kidney | 1 | 2003 | 1247 | 0.040 |
Why?
| | Liver Diseases, Alcoholic | 1 | 1997 | 90 | 0.040 |
Why?
| | Disease-Free Survival | 2 | 2008 | 678 | 0.040 |
Why?
| | Hypercholesterolemia | 1 | 1997 | 94 | 0.040 |
Why?
| | Databases, Factual | 1 | 2021 | 1285 | 0.040 |
Why?
| | Biliary Tract Diseases | 1 | 1996 | 35 | 0.040 |
Why?
| | Cryopreservation | 1 | 1997 | 103 | 0.040 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 1996 | 28 | 0.040 |
Why?
| | Cholestasis, Intrahepatic | 1 | 1996 | 44 | 0.040 |
Why?
| | Diabetes Mellitus | 3 | 2003 | 960 | 0.030 |
Why?
| | Hemostasis, Surgical | 1 | 1995 | 24 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 2 | 2008 | 901 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3239 | 0.030 |
Why?
| | Survival Rate | 3 | 2010 | 1828 | 0.030 |
Why?
| | Thrombosis | 1 | 1998 | 304 | 0.030 |
Why?
| | Proportional Hazards Models | 2 | 2008 | 1190 | 0.030 |
Why?
| | Health Care Rationing | 2 | 2004 | 53 | 0.030 |
Why?
| | Colorado | 4 | 2008 | 4341 | 0.030 |
Why?
| | Melanoma | 1 | 2000 | 700 | 0.030 |
Why?
| | Pleural Effusion | 1 | 2013 | 54 | 0.030 |
Why?
| | Shock, Surgical | 1 | 2012 | 3 | 0.030 |
Why?
| | Hospitals, University | 2 | 2003 | 183 | 0.030 |
Why?
| | Hemodynamics | 1 | 1997 | 1047 | 0.030 |
Why?
| | Intraoperative Care | 1 | 2012 | 48 | 0.030 |
Why?
| | Catecholamines | 1 | 2012 | 116 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2007 | 1237 | 0.030 |
Why?
| | Acute Disease | 3 | 1999 | 986 | 0.030 |
Why?
| | Drug Resistance | 1 | 2012 | 175 | 0.030 |
Why?
| | Cyclosporins | 1 | 1990 | 69 | 0.030 |
Why?
| | Hypertension | 2 | 1997 | 1241 | 0.030 |
Why?
| | Transplantation, Homologous | 3 | 2000 | 450 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2021 | 5335 | 0.020 |
Why?
| | Cohort Studies | 3 | 2008 | 5296 | 0.020 |
Why?
| | Intestine, Small | 1 | 1990 | 138 | 0.020 |
Why?
| | Phlebography | 2 | 1999 | 36 | 0.020 |
Why?
| | United States | 2 | 2022 | 13174 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2003 | 2046 | 0.020 |
Why?
| | Tissue and Organ Harvesting | 1 | 2008 | 69 | 0.020 |
Why?
| | Incidence | 2 | 2007 | 2519 | 0.020 |
Why?
| | Functional Laterality | 1 | 2008 | 223 | 0.020 |
Why?
| | Prospective Studies | 4 | 1999 | 6625 | 0.020 |
Why?
| | Simplexvirus | 1 | 2006 | 85 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2007 | 466 | 0.020 |
Why?
| | Blood Vessels | 1 | 2007 | 191 | 0.020 |
Why?
| | Preoperative Care | 1 | 2007 | 344 | 0.020 |
Why?
| | Survival | 1 | 2004 | 40 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2000 | 3347 | 0.020 |
Why?
| | alpha-Fetoproteins | 1 | 2004 | 36 | 0.020 |
Why?
| | Microsomes, Liver | 1 | 2003 | 60 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1491 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2008 | 427 | 0.020 |
Why?
| | Proteinuria | 1 | 2003 | 92 | 0.010 |
Why?
| | Ultrasonography, Doppler | 1 | 2003 | 107 | 0.010 |
Why?
| | Cost Control | 1 | 2003 | 47 | 0.010 |
Why?
| | Kidney Glomerulus | 1 | 2003 | 113 | 0.010 |
Why?
| | Bile Ducts | 1 | 2003 | 73 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2003 | 159 | 0.010 |
Why?
| | Cost Savings | 1 | 2003 | 85 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 2002 | 101 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 2002 | 158 | 0.010 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2000 | 27 | 0.010 |
Why?
| | Methylprednisolone | 1 | 2001 | 90 | 0.010 |
Why?
| | History, 20th Century | 1 | 2002 | 298 | 0.010 |
Why?
| | Psychology | 1 | 2001 | 89 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 2001 | 201 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2000 | 298 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 2001 | 319 | 0.010 |
Why?
| | Pain, Postoperative | 1 | 2001 | 212 | 0.010 |
Why?
| | Cholesterol | 1 | 2001 | 376 | 0.010 |
Why?
| | Bilirubin | 1 | 1999 | 89 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2003 | 1574 | 0.010 |
Why?
| | Risk | 1 | 2002 | 921 | 0.010 |
Why?
| | Triglycerides | 1 | 2001 | 523 | 0.010 |
Why?
| | Streptokinase | 1 | 1998 | 10 | 0.010 |
Why?
| | Serum Albumin | 1 | 1999 | 149 | 0.010 |
Why?
| | Multiple Organ Failure | 1 | 1999 | 147 | 0.010 |
Why?
| | Postoperative Hemorrhage | 1 | 1999 | 84 | 0.010 |
Why?
| | HLA-DR Antigens | 1 | 1999 | 228 | 0.010 |
Why?
| | Polycythemia Vera | 1 | 1997 | 14 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2003 | 1963 | 0.010 |
Why?
| | Creatine | 1 | 1997 | 54 | 0.010 |
Why?
| | Constriction | 1 | 1997 | 46 | 0.010 |
Why?
| | Liver Circulation | 1 | 1997 | 21 | 0.010 |
Why?
| | Brain Edema | 1 | 1997 | 63 | 0.010 |
Why?
| | Temperance | 1 | 1997 | 17 | 0.010 |
Why?
| | Reperfusion | 1 | 1997 | 45 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1997 | 48 | 0.010 |
Why?
| | Mice, Inbred CBA | 1 | 1997 | 63 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 207 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1999 | 779 | 0.010 |
Why?
| | Coculture Techniques | 1 | 1997 | 204 | 0.010 |
Why?
| | Prevalence | 1 | 2003 | 2440 | 0.010 |
Why?
| | Safety | 1 | 1997 | 313 | 0.010 |
Why?
| | Health Status | 1 | 2001 | 796 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 1997 | 770 | 0.010 |
Why?
| | Carrier State | 1 | 1996 | 60 | 0.010 |
Why?
| | Fibrinolytic Agents | 1 | 1998 | 257 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1771 | 0.010 |
Why?
| | Lymphocytes | 1 | 1997 | 356 | 0.010 |
Why?
| | Comorbidity | 1 | 2000 | 1630 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1998 | 1200 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2003 | 2876 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1997 | 1237 | 0.010 |
Why?
| | Fibrosis | 1 | 1996 | 482 | 0.010 |
Why?
| | DNA | 1 | 2000 | 1399 | 0.010 |
Why?
| | Chronic Disease | 1 | 1999 | 1655 | 0.010 |
Why?
| | Blood Pressure | 1 | 1999 | 1717 | 0.010 |
Why?
| | Rats, Inbred ACI | 1 | 1990 | 5 | 0.010 |
Why?
| | Rats, Inbred BN | 1 | 1990 | 55 | 0.010 |
Why?
| | Rats, Inbred Lew | 1 | 1990 | 99 | 0.010 |
Why?
| | Alcoholism | 1 | 1997 | 808 | 0.010 |
Why?
| | Disease Progression | 1 | 1997 | 2581 | 0.010 |
Why?
| | Quality of Life | 1 | 2001 | 2450 | 0.010 |
Why?
| | Blood Glucose | 1 | 1999 | 1948 | 0.010 |
Why?
| | Obesity | 1 | 2003 | 2802 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1997 | 3314 | 0.010 |
Why?
| | Species Specificity | 1 | 1990 | 604 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2001 | 4915 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1997 | 4145 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 1990 | 223 | 0.010 |
Why?
| | Animals | 2 | 1997 | 34126 | 0.000 |
Why?
| | Rats | 1 | 1990 | 5516 | 0.000 |
Why?
| | Mice | 1 | 1997 | 15616 | 0.000 |
Why?
|
|
Wachs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|